Indonesian dengue burden estimates: review of evidence by an expert panel
- PMID: 28545598
- PMCID: PMC5647663
- DOI: 10.1017/S0950268817001030
Indonesian dengue burden estimates: review of evidence by an expert panel
Abstract
Routine, passive surveillance systems tend to underestimate the burden of communicable diseases such as dengue. When empirical methods are unavailable, complimentary opinion-based or extrapolative methods have been employed. Here, an expert Delphi panel estimated the proportion of dengue captured by the Indonesian surveillance system, and associated health system parameters. Following presentation of medical and epidemiological data and subsequent discussions, the panel made iterative estimates from which expansion factors (EF), the ratio of total:reported cases, were calculated. Panelists estimated that of all symptomatic Indonesian dengue episodes, 57·8% (95% confidence interval (CI) 46·6-59·8) enter healthcare facilities to seek treatment; 39·3% (95% CI 32·8-42·0) are diagnosed as dengue; and 20·3% (95% CI 16·1-24·3) are subsequently reported in the surveillance system. They estimated most hospitalizations occur in the public sector, while ~55% of ambulatory episodes are seen privately. These estimates gave an overall EF of 5·00; hospitalized EF of 1·66; and ambulatory EF of 34·01 which, when combined with passive surveillance data, equates to an annual average (2006-2015) of 612 005 dengue cases, and 183 297 hospitalizations. These estimates are lower than those published elsewhere, perhaps due to case definitions, local clinical perceptions and treatment-seeking behavior. These findings complement global burden estimates, support health economic analyses, and can be used to inform decision-making.
Keywords: Delphi; Epidemiology; Indonesia; dengue; under-reporting.
Conflict of interest statement
J.N., S.B., S.N. and A.M. are/were employees of Sanofi Pasteur, a company which produces a vaccine against dengue. A.P. has acted as an investigator for research studies funded by Sanofi Pasteur. T.Y.M.W., H.T. and M.N. declared no conflicts.
Figures
References
-
- World Health Organization. Global Strategy for Dengue Prevention and Control 2012–2020. Geneva: World Health Organization; 2012.
-
- Suwandono A, et al. Four dengue virus serotypes found circulating during an outbreak of dengue fever and dengue haemorrhagic fever in Jakarta, Indonesia, during 2004. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; 100: 855–862. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical